Common name
acetamide
IUPAC name
acetamide
SMILES
NC(=O)C
Common name
acetamide
IUPAC name
acetamide
SMILES
NC(=O)C
INCHI
InChI=1S/C2H5NO/c1-2(3)4/h1H3,(H2,3,4)
FORMULA
C2H5NO
Common name
acetamide
IUPAC name
acetamide
Molecular weight
59.067
clogP
-0.723
clogS
0.321
Frequency
0.0460
HBond Acceptor
1
HBond Donor
2
Total PolarSurface Area
43.09
Number of Rings
0
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00220 | Atenolol |
|
Antihypertensive Agents; Adrenergic beta-1 Receptor Antagonists; Sympatholytics; Anti-Arrhythmia Agents; Cardiovascular System; Beta Blocking Agents, Selective; Beta Blocking Agents; Beta Blocking Agents, Selective, and Thiazides; Beta Blocking Agents and Thiazides; | For the management of hypertention and long-term management of patients with angina pectoris. |
| FDBD00294 | Phenoxymethylpenicillin |
|
Anti-Bacterial Agents; Penicillins; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials, Penicillins; Beta-Lactamase Sensitive Penicillins; | For the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) due to microorganisms. |
| FDBD00307 | Cefpiramide |
|
Anti-Bacterial Agents; Cephalosporins; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Third-Generation Cephalosporins; | For treatment of severe infections caused by susceptible bacteria such as P. aeruginosa. |
| FDBD00331 | Cefalotin |
|
Anti-Bacterial Agents; Cephalosporins; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; First-Generation Cephalosporins; | Used to prevent infection during surgery and to treat many kinds of infections of the blood, bone or joints, respiratory tract, skin, and urinary tract. |
| FDBD00369 | Darifenacin |
|
Muscarinic Antagonists; Antispasmodic Agents; Genito Urinary System and Sex Hormones; Drugs for Urinary Frequency and Incontinence; Urological Agents; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. |
| FDBD00376 | Ritonavir |
|
Protease Inhibitors; HIV Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); CYP3A4 Inhibitors; Combined Inducers of CYP3A4 and P-glycoprotein; Combined Inhibitors of CYP3A4 and P-glycoprotein; | Indicated in combination with other antiretroviral agents for the treatment of HIV-infection. |
| FDBD00382 | Vancomycin |
|
Anti-Bacterial Agents; Antibiotics; Alimentary Tract and Metabolism; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antidiarrheals, Intestinal Anti-Inflammatory/antiinfective Agents; Intestinal Antiinfectives; Glycopeptide Antibacterials; | For the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. |
| FDBD00405 | Gadoversetamide |
|
Contrast Media; Paramagnetic Contrast Media; Magnetic Resonance Imaging Contrast Media; | Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors. |
| FDBD00425 | Zanamivir |
|
Antiviral Agents; Enzyme Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Neuraminidase Inhibitors; | For the prevention and treatment of influenza A and B. |
| FDBD00427 | Tigecycline |
|
Anti-Bacterial Agents; Tetracyclines; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; | For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by . |
134 ,
14
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1wdn_ligand_1_2.mol2 | 1wdn | 1 | -5.99 | CC(=O)N | 4 |
| 4g4p_ligand_1_2.mol2 | 4g4p | 1 | -5.96 | C(=O)(N)C | 4 |
| 4kqp_ligand_1_2.mol2 | 4kqp | 1 | -5.96 | CC(=O)N | 4 |
| 1jak_ligand_frag_2.mol2 | 1jak | 1 | -5.94 | C(=O)(N)C | 4 |
| 2ntf_ligand_1_9.mol2 | 2ntf | 1 | -5.91 | C(=O)(N)C | 4 |
| 2jiw_ligand_frag_2.mol2 | 2jiw | 1 | -5.89 | NC(=O)C | 4 |
2564 ,
257
